Loading...
Market
Belantamab Mafodotin Market Share in Myeloma by End of 2025
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports and analyst estimates
Story
GSK's Belantamab Mafodotin Shows Promise in Myeloma Trials with PFS HR=0.52 and OS HR=0.77
Jun 2, 2024, 12:25 PM
In recent clinical trials presented at the ASCO 2024 conference, GSK's blood cancer drug belantamab mafodotin has shown promising results in treating relapsed or refractory myeloma. The DREAMM-7 trial revealed that patients treated with a regimen including belantamab mafodotin had a median progression-free survival (PFS) of about 3 years, compared to approximately 13 months with a regimen including an anti-CD38 antibody. Additionally, the DREAMM-8 trial reported a 1-year PFS that was 20 percentage points higher for patients treated with belantamab mafodotin, pomalidomide, and dexamethasone compared to those treated with bortezomib, pomalidomide, and dexamethasone. The PFS HR was 0.52, and the immature OS HR was 0.77. The data suggests a potential comeback for belantamab mafodotin, which had previously been pulled from the market, and experts believe it 'should return' to the US market.
View original story
Similar markets
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Low penetration (<1%) • 25%
Moderate penetration (1-3%) • 25%
High penetration (3-5%) • 25%
Very high penetration (>5%) • 25%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Donanemab surpasses Leqembi in market share • 33%
Donanemab equals Leqembi in market share • 33%
Leqembi remains ahead in market share • 33%
Yes • 50%
No • 50%
